The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F25%3A43921513" target="_blank" >RIV/00023752:_____/25:43921513 - isvavai.cz</a>
Alternative codes found
RIV/00216224:90249/25:00142657 RIV/00216208:11110/25:10498011 RIV/00216208:11120/25:43928433 RIV/00064173:_____/25:43928433
Result on the web
<a href="https://www.mdpi.com/2072-6694/17/9/1488" target="_blank" >https://www.mdpi.com/2072-6694/17/9/1488</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/cancers17091488" target="_blank" >10.3390/cancers17091488</a>
Alternative languages
Result language
angličtina
Original language name
The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients
Original language description
Background/Objectives: Cancer- or chemotherapy-related cognitive deficit is a common side effect occurring in patients with Hodgkin lymphoma. No previous study compared the influence of different types of treatment on the onset and development of chemotherapy cognitive impairment in longitudinal design. The aim of this study was to assess whether a more intensive form of chemotherapy causes greater cognitive impairment. Methods: Forty-four patients at three different stages of the disease and with three different treatments (ABVD + 30 Gy, BEACOPPesc, or ABVD + 30 Gy plus BEACOPPesc) completed the neuropsychological battery and psychological measures of affective distress and quality of life. We compared their cognitive performance before, immediately after, and 6 months after the treatment. Results: Whether or not we divided the total number of people with Hodgkin lymphoma into two groups (mild and moderate disease versus severe disease) or three groups (mild, moderate, and advanced disease), we found no statistically significant difference between the groups in cognitive performance or other psychological factors or experienced quality of life. Conclusions: Our results did not show that disease stage or treatment protocol had an effect on the depth of cognitive impairment in cancer or chemotherapy. We hypothesize that, in terms of brain health, intensive forms of chemotherapy (6 × BEA-COPPesc) do not pose a greater risk than milder forms (4 × ABVD + 30 Gy IF RT and 2 × BEACOPPesc + 4 × ABVD + 30 Gy IF RT) of cancer treatment for Hodgkin lymphoma. However, a limitation of our study is the small number of participants in the study, so it would be advisable to repeat the study on a larger sample of patients. Confirmation of our results could be beneficial in that neither patients nor physicians need to worry that intensive chemotherapy will worsen cognitive deficits.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30215 - Psychiatry
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancers
ISSN
2072-6694
e-ISSN
2072-6694
Volume of the periodical
17
Issue of the periodical within the volume
9
Country of publishing house
CH - SWITZERLAND
Number of pages
14
Pages from-to
"Article Number: 1488"
UT code for WoS article
001485989400001
EID of the result in the Scopus database
2-s2.0-105005095094